Medigene is an immuno-oncology platform company dedicated to discovering and developing T cell immunotherapies for solid tumors. Founded by scientists who are committed to revolutionizing cancer treatment, Medigene aims to fundamentally improve the lives of cancer patients. What sets Medigene apart is their end-to-end platform, which consists of multiple, combinable, exclusive, and proprietary technologies.

These technologies enhance the safety and efficacy of their TCR-T drug products, as well as optimize their development processes from target screening to clinical development. Medigene's TCR technology allows them to generate TCR-T cells with high sensitivity, specificity, and safety. Their ultimate goal is to develop highly innovative and complementary treatment platforms for various cancer types, making use of their comprehensive pipeline of immunotherapies.

Medigene actively seeks strategic partnerships with like-minded parties who believe in the transformative potential of cancer immunotherapies. With a focus on pioneering differentiated TCR-T therapies, Medigene is at the forefront of living immunotherapies for cancer patients